Intermittent Exposure to Xenon Protects against Gentamicin-Induced Nephrotoxicity

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Jia, Ping ^a   Teng, Jie ^a   Zou, Jianzhou ^a   Fang, Yi ^a   Jiang, Suhua ^a   Yu, Xiaofang ^a   Kriegel, Alison J ^b   Liang, Mingyu ^b   Ding, Xiaoqiang ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENTAMICIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MICRORNA 21; N ACETYL BETA GLUCOSAMINIDASE; NITROGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE DOMAIN CONTAINING PROTEIN 1; PROLYL HYDROXYLASE DOMAIN CONTAINING PROTEIN 2; PROLYL HYDROXYLASE DOMAIN CONTAINING PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; VASCULOTROPIN; XENON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; ENZYME REPRESSION; GENE EXPRESSION; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE DISORDER; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; RAT; RENAL PROTECTION; REPERFUSION INJURY; UPREGULATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CYTOPROTECTION; DOWN-REGULATION; GENTAMICINS; KIDNEY; KIDNEY TUBULES; MALE; MICRORNAS; OXIDATIVE STRESS; RATS; RATS, WISTAR; TIME FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENON;

NEGIBACTERIA; RATTUS; RATTUS NORVEGICUS;

EID: 84878490659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064329     Document Type: Article

References (51)

1. Binswanger U, (1997) Acute renal failure: changing causes? Kidney Blood Press Res 20: 163.
2. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ, (2011) New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79: 33-45.
3. Quiros Y, Vicente-Vicente L, Morales AI, López-Novoa JM, López-Hernández FJ, (2011) An Integrative Overview on the Mechanisms Underlying the Renal Tubular Cytotoxicity of Gentamicin. Toxicol Sci 119: 245-256.
4. Martínez-Salgado C, López-Hernández FJ, López-Novoa JM, (2007) Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol 223: 86-98.
5. El Mouedden M, Laurent G, Mingeot-Leclercq MP, Taper HS, Cumps J, et al. (2000) Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob Agents Chemother 44: 665-675.
6. Edwards JR, Diamantakos EA, Peuler JD, Lamar PC, Prozialeck WC, (2007) A novel method for the evaluation of proximal tubule epithelial cellular necrosis in the intact rat kidney using ethidium homodimer. BMC Physiol 7: 1-14.
7. Bledsoe G, Crickman S, Mao J, Xia C, Murakami H, et al. (2006) Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 21: 624-633.
8. Kalayarasan S, Prabhu PN, Sriram N, Manikandan R, Arumugam M, et al. (2009) Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. Eur J Pharmacol 606: 162-171.
9. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Di Paola R, et al. (2002) A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 450: 67-76.
10. Chen LF, Kaye D, (2009) Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 23: 1053-1075.
11. Ali BH, Al Za'abi M, Blunden G, Nemmar A, (2011) Experimental Gentamicin Nephrotoxicity and Agents that Modify it: A Mini-Review of Recent Research. Basic Clin Pharmacol 109: 225-232.
12. Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, et al. (1998) The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 80: 255-256.
13. Lachmann B, Armbruster S, Schairer W, Landstra M, Trouwborst A, et al. (1990) Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 335: 1413-1415.
14. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, et al. (2003) Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 98: 6-13.
15. Neukirchen M, Hipp J, Schaefer MS, Brandenburger T, Bauer I, et al. (2012) Cardiovascular stability and unchanged muscle sympathetic activity during xenon anaesthesia: role of norepinephrine uptake inhibition. Br J Anaesth 109: 887-896.
16. Ma D, Hossain M, Pettet GK, Luo Y, Lim T, et al. (2006) Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab 26: 199-208.
17. Yang T, Zhuang L, Rei Fidalgo AM, Petrides E, Terrando N, et al. (2012) Xenon and Sevoflurane Provide Analgesia during Labor and Fetal Brain Protection in a Perinatal Rat Model of Hypoxia-Ischemia. PLoS One 7: e37020.
18. Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, et al. (2005) Mechanisms of xenon- and isoflurane-induced preconditioning: A potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway. Br J Pharmacol 146: 445-455.
19. Weber NC, Frässdorf J, Ratajczak C, Grueber Y, Schlack W, et al. (2008) Xenon induces late cardiac preconditioning in vivo: A role for cyclooxygenase 2? Anesth Analg 107: 1807-1813.
20. Preckel B, Schlack W, (2004) Editorial III: Xenon- Cardiovascularly inert? Br J Anaesth 92: 786-789.
21. Ma D, Lim T, Xu J, Tang H, Wan Y, et al. (2009) Xenon Preconditioning Protects against Renal Ischemic-Reperfusion Injury via HIF-1α Activation. J Am Soc Nephrol 20: 713-720.
22. Yaman I, Balikci E, (2010) Protective effects of nigella sativa against gentamicin-induced nephrotoxicity in rats. Exp Toxicol Pathol 62: 183-190.
23. Karahan I, Ateşşahin A, Yilmaz S, Ceribaşi AO, Sakin F, (2005) Protective effect of lycopene on gentamicin-induced oxidative stress and nephrotoxicity in rats. Toxicology 215: 198-204.
24. Jiang S, Chen Y, Zou J, Xu X, Zhang X, et al. (2009) Diverse Effects of ischemic pretreatments on the long-term renal damage induced by ischemia-reperfusion. Am J Nephrol 30: 440-449.
25. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, et al. (2010) Renal Medullary MicroRNAs in Dahl Salt-Sensitive Rats: miR-29b Regulates Several Collagens and Related Genes. Hypertension 55: 974-982.
26. Yagi K, (1998) Simple assay for the level of total lipid peroxides in serum of plasma. Methods Mol Biol 108: 101-106.
27. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, et al. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465.
28. Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB, (2002) Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 80: 421-426.
29. Chan JA, Krichevsky AM, Kosik KS, (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033.
30. Cheng Y, Zhu P, Yang J, Liu X, Dong S, et al. (2010) Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 87: 431-439.
31. Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, et al. (2010) Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med 235: 886-891.
32. Jankauskas SS, Plotnikov EY, Morosanova MA, Pevzner IB, Zorova LD, et al. (2012) Mitochondria-targeted antioxidant SkQR1 ameliorates gentamycin-induced renal failure and hearing loss. Biochemistry (Mosc). 77: 666-670.
33. Plotnikov EY, Chupyrkina AA, Jankauskas SS, Pevzner IB, Silachev DN, et al. (2011) Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta 1812: 77-86.
34. Silachev DN, Isaev NK, Pevzner IB, Zorova LD, Stelmashook EV, (2012) The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk. PLoS One 7: e51553.
35. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, et al. (2002) Expression of Hypoxia-Inducible Factor-1α and-2α in Hypoxic and Ischemic Rat Kidneys. J Am Soc Nephrol 13: 1721-1732.
36. Wang Z, Tang L, Zhu Q, Yi F, Zhang F, et al. (2011) Hypoxia-inducible factor-1a contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int 79: 300-310.
37. Steenhard BM, Freeburg PB, Isom K, Stroganova L, Borza DB, et al. (2007) Kidney development and gene expression in the HIF2alpha knockout mouse. Dev Dyn 236: 1115-1125.
38. Scortegagna M, Morris MA, Oktay Y, Bennett M, Garcia JA, (2003) The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Blood 102: 1634-1640.
39. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, et al. (2008) A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 358: 162-168.
40. Paliege A, Rosenberger C, Bondke A, Sciesielski L, Shina A, et al. (2010) Hypoxia-inducible factor-2a-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 77: 312-318.
41. Kojima I, Tanaka T, Inagi R, Kato H, Yamashita T, et al. (2007) Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol 18: 1218-1226.
42. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, et al. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465.
43. Li N, Yi F, Sundy CM, Chen L, Hilliker ML, et al. (2007) Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys. Am J Physiol Renal Physiol 292: F207-F216.
44. Wang Z, Schley G, Türkoglu G, Burzlaff N, Amann KU, et al. (2012) The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant 27: 929-936.
45. Yu X, Fang Y, Liu H, Zhu J, Zou J, et al. (2012) The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 0: 1-9.
46. Liang M, Liu Y, Mladinov D, Cowley AW Jr, Trivedi H, et al. (2009) MicroRNA: a new frontier in kidney and blood pressure research. MicroRNA: a new frontier in kidney and blood pressure research. Am J Physiol Renal Physiol 297: F553-F558.
47. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, et al. (2010) Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A. 107: 14339-14344.
48. Kriegel AJ, Liu Y, Cohen B, Usa K, Liu Y, et al. (2012) MiR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis. Physiol Genomics 44: 259-267.
49. Xu X, Kriegel AJ, Liu Y, Usa K, Mladinov D, et al. (2012) Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int 82: 1167-1175.
50. Wappler F, Rossaint R, Baumert J, Scholz J, Tonner PH, et al. (2007) Xenon Multicenter Study Research Group: Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology 106: 463-471.
51. Faulkner SD, Downie NA, Mercer CJ, Kerr SA, Sanders RD, et al. (2012) A xenon recirculating ventilator for the newborn piglet: developing clinical applications of xenon for neonates. Eur J Anaesthesiol 29: 577-585.